RPRX

NASD Royalty Pharma Plc Class A
Oct 13, 2026 · 12:23 AM ET EOD Market Closed

$57.78 ↑ +0.00 (+0.00%) Trading Up from the previous close of $57.78, $0.14 below the day’s high of $57.92

YTD change
+49.53%
vs 20-day SMA
-0.14%
vs 200-day SMA
+12.12%

Price ranges

Previous day
$55.72 $57.08
open $56.03 close $56.93
+$0.90 (+1.61%)
Today
$56.85 $57.92
open $57.16 now $57.78
+$0.62 (+1.08%)
Past week
$55.13 $57.25
from $57.16 now $57.78
+$0.62 (+1.08%)
Past month
$55.13 $59.55
from $58.61 now $57.78
-$0.83 (-1.42%)
This year
$38.29 $64.38
from $38.64 now $57.78
+$19.14 (+49.53%)

Price & Performance

+9.35 (+19.31%) / 6M

$47.19$53.19$59.20$65.20Apr 13Jul 14Oct 12

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 10.3% away from all-time highs of $64.38
  • RPRX is up 50% since the beginning of the year
  • RPRX is up 60% over the past 12 months
  • RPRX is down 1% over the past 1 month
  • 4% of all RPRX investors are betting against RPRX

RPRX reads very good: price sits above one of the two key moving averages, the 12-month move is +63.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $1.14057
Earnings momentum -8.9% Quarterly EPS growth
Quarterly change -8.9%

Valuation

P/E ratio 14.73
Enterprise value $31.0B
Beta 0.70

Balance sheet & scale

Income$1.0M
Revenue$2.3B
Cash$645.1M
Debt$8.0M
Income / Debt 0.13×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Real Estate and Rental and Leasing
Sub Sector Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
Market cap $25.0B

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Competitor comparison

TickerCompany PriceChange
TPL Texas Pacific Land Corporation $365.32 +1.20%
WH Wyndham Hotels & Resorts, Inc. $73.35 -0.96%
PREKF PrairieSky Royalty Ltd $23.84 +0.46%
CHH Choice Hotels International, Inc. $103.38 -2.14%
PBT Permian Basin Royalty Trust $35.65 +2.27%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.